Tag: SAPX

ASKE, SCXN, SPY Calls & Extended Watchlist

Alaska Pacific Energy Corp. ASKE

Triple-zero stocks can serve well as “lottery ticket” plays, and have been known by us in the past, to sometimes be capable of large and rapid gains. ASKE falls under that category. Earlier this year, the stock ran 500% from .0001-.0006. Following that run the stock pulled back to .0002 before making a 150% move to .0005, so as you can see, ASKE is certainly able to deliver multi-bag gains. Every uptick from the current price would spell 30% in gains, So while they generally carry high volatility, triple-zero stocks certainly have some serious  “silver lining” potential.

Currently the stock is sitting at .0002, its 200DMA, with resistance at the 50DMA, of .0003.Should ASKE move past that level, it could very easily return to recent swing highs in the .0005-.0006 range, which would represent a quick 66-100% in gains.

Out this morning: Alaska Pacific Energy Corp: Message From the President

___

Scout Exploration, Inc. SCXN

We have mentioned SCXN plenty in the past, and it seemed like a decent time to re-mention it. The stock is hovering around a low, and has been holding above the 200DMA.

We also ran across a research report on SCXN that you may find informative.

___

Weekly SPY Calls

The SPY Index pulled back early in yesterday’s trading session, though it was very short lived, as the S&P500 rallied late in the day.This morning the SPY is gapping up to new highs, and we once again want to turn our attention to the 155.00 and 156.00 Weekly SPY Calls.

Yesterday, the 155’s closed at a 1.06, and the 156’s closed at .32. We expect to see gap-ups on each to the tune of 50% or better. If the last eight or nine trading sessions have any influence on today, we would expect to see a pullback followed by a potential bounce-play opportunity.   

___

Extended Watchlist:
SAPX, PNCH, MFTH, FEEL,  BBRY, SVA, AFFY

FOLD, MWIP & Extended Watchlist

FOLD caught our attention yesterday as an intriguing pharmaceutical play that recently underwent some panic selling, and is now coming off of the resultant bottom.First a little back-story: Amicus has been teamed up with pharma giant, GlaxoSmithKline (GSK), running clinical trials on a drug called migalastat HCI, meant to treat a rare disease in which a genetic mutation prevents enzymes from breaking down a fatty substance referred to as GL-3. As a result, GL-3 build up in the kidneys can lead to organ failure and death.

The big sell-off occurred back in late December when the duo announced that the study, statistically, failed to meet their objectives after a 6 month period, making a fast-track to FDA approval an impossibility.

The encouraging news, and the reason we think now is a prime time to take a look at FOLD, is that the studies do not conclude at the 6 month point; they have continued, and the 12 month results are expected to come early in 2013. While failing to meet project goals, there was still a 50% reduction in GL-3 buildup in 41% of the migalastat HCI group, as compared to just 28% of the placebo group. The 12-month results will be accompanied by the company meeting FDA officials to discuss the track to approval, and how it is altered by the results of trials still underway.

John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 9, 2013 at 3:00 p.m. PT. which can be viewed via a LIVE WEBCAST on the specified date and time.

What really jumps out to us, is simply the fact that FOLD recently saw a big gap down, and has now begun to recover. Often in the past we’ve seen cases such as this where the stock bounces back to fill the gap, offering up great opportunities for gain.

It could also come to that sooner, rather than later- The company also has other irons in the fire, as this morning it released a PR regarding another of its drugs currently in testing phases, this time with positive results:


Amicus Therapeutics Announces Positive Results From All Four Cohorts in Phase 2 Chaperone-Enzyme Replacement Therapy (ERT) Co-Administration Study for Pompe Disease

CRANBURY, N.J., Jan 04, 2013 (GLOBE NEWSWIRE via COMTEX) — Strong Proof-of-Concept Data for Chaperone’s Ability to Stabilize and Enhance Activity and Uptake of Currently Marketed ERT Products for Pompe Disease

Results to be Presented at LDN WORLD Symposium in February 2013

Initiation of Repeat-Dose Pompe Study Anticipated in 3Q13

Amicus Therapeutics (Nasdaq: FOLD) today announced positive preliminary results from all 4 dose cohorts in a Phase 2 study (Study 010) to evaluate the safety and pharmacokinetic (PK) effects of the pharmacological chaperone AT2220 (duvoglustat HCl) co-administered with enzyme replacement therapy (ERT) for Pompe disease (Myozyme and Lumizyme). Myozyme and Lumizyme (alglucosidase alfa, or recombinant human GAA enzyme, rhGAA) are the first and only approved treatments for Pompe disease.

___

We will be continuing to follow this play, and keep everyone updated as more details arise.

___

MediSwipe, Inc. MWIP

A lot of you may have missed our last report before the holidays, in which we mentioned that we would like to see MWIP continue to hold support above a penny and test its previous highs. Yesterday saw the stock break past its previous high of .0199 into blue-sky territory, hitting a high of .0289, earning us a spot on the Penny Stock Rumble with a gain of 50%

In total, from the low following our first mention of MWIP back at .0024, yesterday’s high marks an astonishing 1104% gain.

If and when we see a pullback on MWIP, we want to see the previous resistance of .0199 hold as a future level of support for us to remain bullish.

___

Extended Watchlist:

UNLA, AHFD, AXCG, SAPX, SFAZ, ZLCS

GMXS, ERBB & Extended Watchlist

Gemini Explorations, Inc. GMXS

GMXS is an old-time favorite of ours, which reappeared on our extended watchlists on Friday, November 16th, after we observed the stock coming off of its bottom one day prior. Those of you who have been following us for some time may recall that this is the play we followed from .04-.10 back in March.

On the 16th, GMXS was as low as .03, and closed at the high of .04. Last week we continued to see slow and steady gains, finishing off the week at .059. As we stated in an afternoon update last Monday, we could be looking at a re-test of the previous ten-cent high.

The indicators on the chart are looking strong, with a possible golden cross in the making. The RSI is in the power zone, suggesting that recent momentum could continue.

____

 

Tranzbyte Corp ERBB

Since we did our follow-upon our initial medical marijuana round-up report, we’ve been sure to continue to include ERBB in the stocks we are tracking. On the 31st following our alert, we saw a .0016 low before witnessing a jump to .013 (+713%). It slid back and found support above the 20DMA, bounced off of .0035 and hit a subsequent high of .007 this past Wednesday.We’ve been calling for a golden cross since the 13th, stating: “we have a golden cross formation setting up on the chart. This play will be on our watchlist for weeks to come.” The 20DMA also has a chance to break the 200DMA as predicted, possibly this week. Once we see that occur, we expect to see some major upward momentum in the stock.

____

Extended Watchlist:

SRGE, SAPX, TLFX, EGCT,